Previous Close | 0.8100 |
Open | 0.7900 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 0.7700 - 0.8450 |
52 Week Range | 0.4200 - 1.8900 |
Volume | |
Avg. Volume | 249,838 |
Market Cap | 11.93M |
Beta (5Y Monthly) | -0.03 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
─On Track for Midyear 2024 Topline Data and Late 2024/Early 2025 Open Label Data Readouts from CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis (PSC), Following Early Completion of Patient Enrollment Six Months Ahead of Schedule─ ─New Peer-Reviewed Publications Based on Patient Sample Studies Further Reinforce the Key Role of Chemomab’s Novel CCL24 Target in Both PSC and Systemic Sclerosis─ ─PSC Expert Webinar Highlights the Emerging Importance of Surrogate Biomarkers in PSC Clinical Devel
TEL AVIV, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that it received formal notification from the Listing Qualification Department of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that it has been granted an additional 180-day compliance period, or until November 4, 2024, to regain complianc
TEL AVIV, Israel, May 02, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that Chief Executive Officer Dr. Adi Mor will deliver a corporate presentation at the Aegis Virtual Conference on May 7, 2024 at 9:00 am ET. Dr. Mor’s presentation will be webcast live. The registration link to access the live presentation is included